Dr. Michael Abern is the Clinical Director of the Prostate Cancer Program and Director of Urologic Oncology at the University of Illinois at Chicago (UIC). He is responsible for the clinical management of patients with prostate and other genitourinary malignancies, the direction of multi-disciplinary tumor board, and the translation of discoveries for patient benefit. A racially diverse population of men with African ancestry that suffer a high burden of prostate cancer incidence and mortality are treated at UIC. His research, based off the extracted data, is on the mechanisms of possible disparities in regard to the Vitamin D axes in benign and malignant prostate tissue. Dr. Abern provides access to clinical prostate cancer patients, assists with identification of appropriate patients for the study, and uses his prostate tumor imaging program to assist with harvesting representative benign and malignant tissues.
His research is focused on prostate cancer epidemiology, detection and risk stratification.